Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–249

Article  Google Scholar 

Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235:373–382

Article  Google Scholar 

Lee SY, Konstantinidis IT, Eaton AA, Gönen M, Kingham TP, et al. Predicting recurrence patterns after resection of hepatocellular cancer. HPB (Oxford). 2014;16:943–953

Article  Google Scholar 

Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261:947–955

Article  Google Scholar 

Lang H, Sotiropoulos GC, Brokalaki EI, Schmitz KJ, Bertona C, et al. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg. 2007;205:27–36

Article  Google Scholar 

Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992–2008. Hepatology. 2012;55:476–482

Article  Google Scholar 

Lee JG, Kang CM, Park JS, Kim KS, Yoon DS, et al. The actual five-year survival rate of hepatocellular carcinoma patients after curative resection. Yonsei Med J. 2006;47:105–112

Article  Google Scholar 

Shinkawa H, Tanaka S, Takemura S, Amano R, Kimura K, et al. Nomograms predicting extra- and early intrahepatic recurrence after hepatic resection of hepatocellular carcinoma. Surgery. 2021;169:922–928

Article  Google Scholar 

Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10–24

Article  CAS  Google Scholar 

Xu XF, Xing H, Han J, Li ZL, Lau WY, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg. 2019;154:209–217

Article  Google Scholar 

Amini N, Ejaz A, Spolverato G, Maithel SK, Kim Y, Pawlik TM. Management of lymph nodes during resection of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Surg. 2014;18:2136–2148

Article  Google Scholar 

Chen ZH, Zhang XP, Feng S, Feng JK, Chai ZT, et al. Liver resection versus intensity-modulated radiation therapy for treatment of hepatocellular carcinoma with hepatic vein tumor thrombus: a propensity score matching analysis. Hepatobiliary Surg Nutr. 2021;10:646–660

Article  CAS  Google Scholar 

Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65:938–943

Article  Google Scholar 

Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al. 2018. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md.) 67:358–80

European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. 2018. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69:182-236

Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 2007;245:831–842

Article  Google Scholar 

Wang Z, Ren Z, Chen Y, Hu J, Yang G, et al. Adjuvant transarterial chemoembolization for hbv-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res. 2018;24:2074–2081

Article  CAS  Google Scholar 

Wei W, Jian PE, Li SH, Guo ZX, Zhang YF, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun (Lond Engl). 2018;38:61

Article  Google Scholar 

Yin J, Li N, Han Y, Xue J, Deng Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013;31:3647–3655

Article  CAS  Google Scholar 

Hui D, Qiang L, Jian W, Ti Z, Da-Lu K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis. 2009;41:36–41

Article  Google Scholar 

Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015;148:1383–91.e6

Article  CAS  Google Scholar 

Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000;356:802–807

Article  CAS  Google Scholar 

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502

Article  CAS  Google Scholar 

Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940–952

Article  Google Scholar 

Qin S, Ren Z, Meng Z, Chen Z, Chai X, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21:571–580

Article  CAS  Google Scholar 

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–1355

Article  CAS  Google Scholar 

Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–207

Article  Google Scholar 

2018. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69:182–236

Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399:1718–1729

Article  CAS  Google Scholar 

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683–694

Article  CAS  Google Scholar 

Kudo M, Ueshima K, Nakahira S, Nishida N, Ida H, et al. 2021. Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis. Journal of Clinical Oncology 39:4070-

Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022

Article  Google Scholar 

Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg. 2000;231:544–551

Article  CAS  Google Scholar 

Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: current status and prospects. Genes Dis. 2020;7:359–369

Article  CAS  Google Scholar 

Shimoda M, Tago K, Shiraki T, Mori S, Kato M, et al. Risk factors for early recurrence of single lesion hepatocellular carcinoma after curative resection. World J Surg. 2016;40:2466–2471

Article  Google Scholar 

Lee HY, Rhim H, Lee MW, Kim YS, Choi D, et al. Early diffuse recurrence of hepatocellular carcinoma after percutaneous radiofrequency ablation: analysis of risk factors. Eur Radiol. 2013;23:190–197

Article  Google Scholar 

Huang L, Li J, Yan J, Cao J, Liu C, et al. Early recurrence after curative resection in oligonodular hepatocellular carcinoma. Hepatogastroenterology. 2013;60:28–31

Google Scholar 

Zhou J, Sun H, Wang Z, Cong W, Wang J, et al. 2020. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver cancer 9:682–720

Cheng S, Chen M, Cai J, Sun J, Guo R, et al. 2020. Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). Liver cancer 9:28–40

Sun J, Guo R, Bi X, Wu M, Tang Z, et al. 2022. Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition). Liver cancer 11:315–28